Duality Biotherapeutics (FRA:4ZB) Total Long-Term Assets: €10.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Total Long-Term Assets?

Duality Biotherapeutics FRA:4ZB +6.49% 19 Total Long-Term Assets is €10.8 Mil as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Duality Biotherapeutics's Total Long-Term Assets for the quarter that ended in Jun. 2026 was €10.8 Mil.

Duality Biotherapeutics Total Long-Term Assets Related Terms

Duality Biotherapeutics Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Total Long-Term Assets Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
7.93 21.19 24.42 7.16

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Total Long-Term Assets 10.40 7.16 10.78
FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €10.8 Mil mean?
Duality Biotherapeutics (FRA:4ZB) has a Total Long-Term Assets of €10.8 Mil as of Jun. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Total Long-Term Assets too high?
Duality Biotherapeutics' current Total Long-Term Assets is €10.8 Mil. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Total Long-Term Assets compare to VRTX and REGN?
Duality Biotherapeutics' Total Long-Term Assets of €10.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Biotechnology company?
A good Total Long-Term Assets depends on the Biotechnology industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Total Long-Term Assets is €10.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Total Long-Term Assets of €10.8 Mil. The current Total Long-Term Assets is €10.8 Mil. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Total Long-Term Assets is €10.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price